Cancer research
Scientists at First Jining People's Hospital in Jining, People's Republic of China, have made a groundbreaking discovery in the fight against breast cancer. According to a recent study, a DNA tetrahedron (DT) nanostructure has been successfully used to co-deliver shikonin and CpG oligonucleotide, achieving chemoimmunotherapy of
Cancer research
Researchers from the First Hospital of China Medical University have made a groundbreaking discovery in the field of cancer gene therapy. By studying the microbiome within tumor tissues, they have found that microorganisms play a crucial role in regulating the tumor microenvironment and promoting the progression of solid tumors. The
Cancer research
A study published in the Journal of the American Medical Association (JAMA) Oncology has introduced a new approach to treating advanced hepatocellular carcinoma (HCC). The research, conducted by investigators at the University of Palermo, aimed to compare the health-related quality of life (HR-QoL) effects associated with different first-line treatments for
Cancer research
Research presented in a Phase II clinical trial has demonstrated that retifanlimab, a humanized monoclonal antibody targeting programmed cell death protein-1 (PD-1), can induce frequent and durable responses in chemotherapy-naive patients with recurrent locally advanced or metastatic Merkel cell carcinoma (MCC). The study, known as POD1UM-201, enrolled 101 patients across
Cancer research
A new study published in the Cancer Treatment and Research Communications journal has found that a biosimilar version of bevacizumab, known as CT-P16, has equivalent long-term efficacy to the European-approved reference bevacizumab in patients with metastatic or recurrent non-squamous non-small cell lung cancer (NSCLC). Researchers at the Clinical Hospital Center
Cancer research
Researchers at Tianjin University have conducted a retrospective cohort study to evaluate the effectiveness of atezolizumab combined with etoposide and platinum (EP) chemotherapy compared to EP alone as first-line treatment in patients with extensive-stage small cell lung cancer (ES-SCLC). The study included 95 patients diagnosed with ES-SCLC at Tianjin Chest
Cancer research
Researchers at Universitatsklinikum Erlangen, in collaboration with various international institutions, have conducted a study to investigate the prognostic impact of the choice of chemotherapy after first-line CDK4/6 inhibitor therapy in patients with metastatic hormone receptor-positive, HER2-negative breast cancer. The study, published in the European Journal of Cancer, analyzed data
Cancer research
Researchers from the Cancer Hospital of China Medical University have made significant findings in the field of cancer gene therapy, particularly in the treatment of melanoma. According to their study, published in the journal Frontiers in Immunology, nano-immunotherapy has emerged as a promising approach for melanoma treatment. By leveraging nanotechnology,
Cancer research
Researchers at the University of Utah have made a significant breakthrough in developing a novel gene therapy for treating hepatocellular carcinoma (HCC), a type of liver cancer. The therapy, called mitochondrially targeted p53-Bad* fusion gene therapy, has shown promising results in promoting apoptosis in HCC cells by inhibiting the Bcl-2
Cancer research
A new report presents fresh data on hydrogel-based therapy for thyroid cancer, highlighting its potential as a multifunctional platform to overcome challenges in cancer management. The research, conducted by a team of scientists from Tongde Hospital Zhejiang Province, China, has synthesized current advancements in hydrogel-based therapy, focusing on its potential
Cancer research
Fresh data on pancreatic cancer have shed new light on the mechanisms driving cancer resistance to immunotherapy. A recent study published in Frontiers in Immunology has found that tumor-intrinsic interferon (IFN) signaling may contribute to pancreatic cancer cells' ability to evade treatment. Researchers at the University of North Carolina
Cancer research
Researchers from the University of Malaya, in collaboration with Cancer Research Malaysia, have conducted a phase II clinical trial to evaluate the efficacy of pembrolizumab monotherapy in metastatic HER2-negative breast cancer patients with germline APOBEC3B deletion. The study, published in The Lancet Regional Health - Western Pacific, found that pembrolizumab
